## Cinzia Ciccacci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4308843/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A multilocus genetic study evidences the association of autoimmune-related genes with Psoriatic Arthritis in Italian patients. Immunobiology, 2022, 227, 152232.	0.8	3
2	The Impacts of the Clinical and Genetic Factors on Chronic Damage in Caucasian Systemic Lupus Erythematosus Patients. Journal of Clinical Medicine, 2022, 11, 3368.	1.0	4
3	Impact of TRAF3IP2, IL10 and HCP5 Genetic Polymorphisms in the Response to TNF-i Treatment in Patients with Psoriatic Arthritis. Journal of Personalized Medicine, 2022, 12, 1094.	1.1	1
4	Altered expression of miR-142, miR-155, miR-499a and of their putative common target <i>MDM2</i> in systemic lupus erythematosus. Epigenomics, 2021, 13, 5-13.	1.0	8
5	mRNA expression analysis confirms CD44 splicing impairment in systemic lupus erythematosus patients. Lupus, 2021, 30, 1086-1093.	0.8	5
6	Emerging Role of microRNAs and Long Non-Coding RNAs in Sjögren's Syndrome. Genes, 2021, 12, 903.	1.0	9
7	Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations. Frontiers in Genetics, 2021, 12, 671976.	1.1	14
8	What Is in the Field for Genetics and Epigenetics of Diabetic Neuropathy: The Role of MicroRNAs. Journal of Diabetes Research, 2021, 2021, 1-10.	1.0	8
9	VDR Polymorphisms in Autoimmune Connective Tissue Diseases: Focus on Italian Population. Journal of Immunology Research, 2021, 2021, 1-6.	0.9	10
10	CLEC4E (Mincle) genetic variation associates with pulmonary tuberculosis in Guinea-Bissau (West) Tj ETQq0 0 0	rgBT /Ovei 1.0	lock 10 Tf 50
11	Mitochondrial DNA Copy Number in Peripheral Blood Is Reduced in Type 2 Diabetes Patients with Polyneuropathy and Associated with a <i>MIR499A</i> Gene Polymorphism. DNA and Cell Biology, 2020, 39, 1467-1472.	0.9	18
12	Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy. Epigenomics, 2020, 12, 575-585.	1.0	21
19	The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. Clinical and	0.4	7

	Experimental Rheumatology, 2020, 38, 580.			
14	TNFAIP3 Gene Polymorphisms in Three Common Autoimmune Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Primary Sjogren Syndrome—Association with Disease Susceptibility and Clinical Phenotypes in Italian Patients. Journal of Immunology Research, 2019, 2019, 1-6.	0.9	30	
15	miRNAs in drug response variability: potential utility as biomarkers for personalized medicine. Pharmacogenomics, 2019, 20, 1049-1059.	0.6	20	
16	A common polymorphism in MIR155 gene promoter region is associated with a lower risk to develop type 2 diabetes. Acta Diabetologica, 2019, 56, 717-718.	1.2	7	
17	Genetics and Autoimmunity. , 2019, , 93-104.		0	
18	STAT4, TRAF3IP2, IL10, and HCP5 Polymorphisms in SjĶgren's Syndrome: Association with Disease	0.9	25	

Susceptibility and Clinical Aspects. Journal of Immunology Research, 2019, 2019, 1-8.

CINZIA CICCACCI

#	Article	IF	CITATIONS
19	Effect of <i><scp>CYP</scp>4F2</i> , <i><scp>VKORC</scp>1</i> , and <i><scp>CYP</scp>2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	2.3	23
20	Pharmacogenomics in Parkinson's disease: which perspective for developing a personalized medicine?. Neural Regeneration Research, 2019, 14, 75.	1.6	5
21	Interaction between microbiome and host genetics in psoriatic arthritis. Autoimmunity Reviews, 2018, 17, 276-283.	2.5	38
22	Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies. NeuroMolecular Medicine, 2018, 20, 1-17.	1.8	43
23	Association between a MIR499A polymorphism and diabetic neuropathy in type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 11-17.	1.2	35
24	A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. Journal of Antimicrobial Chemotherapy, 2018, 73, 2137-2140.	1.3	2
25	Evaluation of <i>ATG5</i> polymorphisms in Italian patients with systemic lupus erythematosus: contribution to disease susceptibility and clinical phenotypes. Lupus, 2018, 27, 1464-1469.	0.8	25
26	Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants. Oncotarget, 2018, 9, 7812-7821.	0.8	33
27	Discovering the genetic contribution to cardiovascular diseases in patients affected by autoimmune diseases. Annals of Translational Medicine, 2018, 6, S44-S44.	0.7	0
28	Cannabinoid Poisoning by Hemp Seed Oil in a Child. Pediatric Emergency Care, 2017, 33, 344-345.	0.5	17
29	Pharmacogenetics of inflammatory bowel disease: a focus on Crohn's disease. Pharmacogenomics, 2017, 18, 1095-1114.	0.6	11
30	Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. European Journal of Clinical Pharmacology, 2017, 73, 1253-1259.	0.8	12
31	Polymorphisms in MIR122, MIR196A2, and MIR124A Genes are Associated with Clinical Phenotypes in Inflammatory Bowel Diseases. Molecular Diagnosis and Therapy, 2017, 21, 107-114.	1.6	17
32	A polymorphism upstream MIR1279 gene is associated with pericarditis development in Systemic Lupus Erythematosus and contributes to definition of a genetic risk profile for this complication. Lupus, 2017, 26, 841-848.	0.8	13
33	Polymorphisms in miRNA genes and their involvement in autoimmune diseases susceptibility. Immunologic Research, 2017, 65, 811-827.	1.3	23
34	Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis. PLoS ONE, 2017, 12, e0169956.	1.1	22
35	Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease. MicroRNA (Shariqah,) Tj ETQq1 1 C	).784314 rg 0.6	gBT <sub>5</sub> /Overlock
36	Recent advances in exploring the genetic susceptibility to diabetic neuropathy. Diabetes Research and Clinical Practice, 2016, 120, 198-208.	1.1	28

CINZIA CICCACCI

#	Article	IF	CITATIONS
37	Polymorphisms in STAT-4, IL-10, PSORS1C1, PTPN2 and MIR146A genes are associated differently with prognostic factors in Italian patients affected by rheumatoid arthritis. Clinical and Experimental Immunology, 2016, 186, 157-163.	1.1	36
38	Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	79
39	Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes. Thrombosis Research, 2015, 136, 367-370.	0.8	20
40	Autophagy and inflammatory bowel disease: Association between variants of the autophagy-related IRGM gene and susceptibility to Crohn's disease. Digestive and Liver Disease, 2015, 47, 744-750.	0.4	35
41	A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility. International Journal of Molecular Sciences, 2015, 16, 5830-5838.	1.8	7
42	Stevens–Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. Pharmacogenomics, 2015, 16, 1989-2002.	0.6	10
43	A family study of asymptomatic small bowel Crohn's disease. Digestive and Liver Disease, 2014, 46, 276-278.	0.4	4
44	Common polymorphisms in MIR146a, MIR128a and MIR27a genes contribute to neuropathy susceptibility in type 2 diabetes. Acta Diabetologica, 2014, 51, 663-671.	1.2	70
45	HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. European Journal of Clinical Pharmacology, 2014, 70, 275-278.	0.8	18
46	A Multilocus Genetic Study in a Cohort of Italian SLE Patients Confirms the Association with STAT4 Gene and Describes a New Association with HCP5 Gene. PLoS ONE, 2014, 9, e111991.	1.1	60
47	Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. European Journal of Clinical Pharmacology, 2013, 69, 1909-1916.	0.8	55
48	Resequencing of VKORC1, CYP2C9 and CYP4F2 genes in Italian patients requiring extreme low and high warfarin doses. Thrombosis Research, 2013, 132, 123-126.	0.8	9
49	TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics, 2013, 65, 703-709.	1.2	53
50	TCF7L2 gene polymorphisms and type 2 diabetes: association with diabetic retinopathy and cardiovascular autonomic neuropathy. Acta Diabetologica, 2013, 50, 789-799.	1.2	62
51	TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2013, 7, 44-52.	0.6	51
52	MicroRNA genetic variations: association with type 2 diabetes. Acta Diabetologica, 2013, 50, 867-872.	1.2	60
53	ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity. Pharmacogenetics and Genomics, 2013, 23, 38-39.	0.7	1
54	Impact of the CYP4F2 p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. Clinical Pharmacology and Therapeutics, 2012, 92, 746-756.	2.3	56

CINZIA CICCACCI

#	Article	IF	CITATIONS
55	Anthropological features of the CFTR gene: Its variability in an African population. Annals of Human Biology, 2011, 38, 203-209.	0.4	5
56	Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenetics and Genomics, 2011, 21, 344-346.	0.7	15
57	EPHX1 Polymorphisms Are Not Associated With Warfarin Response in an Italian Population. Clinical Pharmacology and Therapeutics, 2011, 89, 791-791.	2.3	9
58	Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics, 2010, 11, 23-31.	0.6	67
59	Pharmacogenomics: Role in Medicines Approval and Clinical Use. Public Health Genomics, 2010, 13, 284-291.	0.6	10
60	Population differences in allele frequencies at theOLR1locus may suggest geographic disparities in cardiovascular risk events. Annals of Human Biology, 2010, 37, 137-149.	0.4	7
61	<i>CYP4F2</i> genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics, 2009, 10, 261-266.	0.6	129
62	ATG16L1 Ala197Thr Is Not Associated With Susceptibility to Crohn's Disease or With Phenotype in an Italian Population. Gastroenterology, 2008, 134, 368-370.	0.6	26
63	Genetic tests and genomic biomarkers: regulation, qualification and validation. Clinical Cases in Mineral and Bone Metabolism, 2008, 5, 149-54.	1.0	37
64	Allelic variants in the <i>CYP2C9</i> and <i>VKORC1</i> loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics, 2007, 8, 1545-1550.	0.6	59
65	Interleukin-23R Arg381Gln Is Associated With Susceptibility to Crohn's Disease But Not With Phenotype in an Italian Population. Gastroenterology, 2007, 133, 1049-1051.	0.6	21
66	Highly preferential association of NonF508del CF mutations with the M470 allele. Journal of Cystic Fibrosis, 2007, 6, 15-22.	0.3	15
67	Haplotype block structure study of the CFTR gene. Most variants are associated with the M470 allele in several European populations. European Journal of Human Genetics, 2006, 14, 85-93.	1.4	20
68	A large-scale study of the random variability of a coding sequence: a study on the CFTR gene. European Journal of Human Genetics, 2005, 13, 184-192.	1.4	17